Daratumumab 100mg/5ml Injection

Daratumumab 100mg/5ml Injection is a groundbreaking, first-in-class human IgG1k monoclonal antibody that has redefined the treatment landscape for Multiple Myeloma. This biological therapy works by binding with high affinity to the CD38 molecule, a surface protein that is highly expressed on multiple myeloma cells. Once bound, Daratumumab acts as a beacon for the patient’s own immune system, triggering a multi-pronged attack to destroy the cancer. It utilizes three potent mechanisms: Complement-Dependent Cytotoxicity (CDC), Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), and Antibody-Dependent Cellular Phagocytosis (ADCP). Essentially, it recruits natural killer cells, macrophages, and neutrophils to engulf or burst the tumor cells. Additionally, it induces direct apoptosis (programmed cell death) upon cross-linking and modulates the enzymatic activity of CD38, further inhibiting tumor growth. Discover how this professional pharmaceutical intervention provides the ultimate clinical strategy for targeting plasma cell malignancies, offering deep and durable responses even in heavily pre-treated patients.

The 100mg/5ml vial serves as the precise dosing unit for calculating the patient-specific intravenous dosage (typically 16 mg/kg). This smaller vial size is essential for minimizing drug wastage when tailoring the dose to the patient’s exact body weight, often used in conjunction with the larger 400mg vials. This concentration (20 mg/mL) requires dilution in sterile saline prior to administration. The infusion is generally given on a weekly schedule for the first several weeks, then tapered to every two weeks, and finally to a monthly maintenance schedule, ensuring continuous suppression of the CD38-positive clone.

Indications / Uses of Daratumumab 100mg/5ml Injection

Daratumumab 100mg/5ml Injection is commonly prescribed for the specialized management of the following plasma cell disorders:

• Multiple Myeloma (Newly Diagnosed): It is indicated in combination with lenalidomide/dexamethasone or bortezomib/melphalan/prednisone for patients ineligible for stem cell transplant, and with bortezomib/thalidomide/dexamethasone for transplant-eligible patients.
• Relapsed/Refractory Multiple Myeloma: It is used as a monotherapy for patients who have received at least three prior lines of therapy (including a proteasome inhibitor and an immunomodulatory agent) or in combination regimens for earlier relapses.
• Light Chain (AL) Amyloidosis: Daratumumab is the first and only drug approved for the treatment of newly diagnosed AL amyloidosis (in combination with cyclophosphamide, bortezomib, and dexamethasone), helping to halt the production of amyloid-forming proteins.

Key Features

• Targeted CD38 Engagement: The primary feature of Daratumumab 100mg/5ml Injection is its specificity for CD38, a ubiquitous marker on myeloma cells, allowing for precise targeting with minimal impact on CD38-negative tissues.
• Immune-Mediated Killing: Unlike chemotherapy, it harnesses the body’s complement system and effector cells (NK cells, macrophages) to eliminate the tumor.
• Precision Dosing: The 100mg vial size allows for accurate dose calculation and waste reduction for patients with lower body weights or specific dosing requirements.
• Deep Response Rates: Clinical trials show it is capable of achieving Minimal Residual Disease (MRD) negativity, meaning no cancer cells are detectable even with sensitive testing.
• Synergistic Potency: It demonstrates remarkable synergy when combined with immunomodulatory drugs (like Revlimid) and proteasome inhibitors (like Velcade).

Storage for Daratumumab 100mg/5ml Injection

To preserve the structural integrity and biological activity of the monoclonal antibody, Daratumumab 100mg/5ml Injection must be stored under refrigeration, typically between 2°C and 8°C (36°F to 46°F). Do not freeze and do not shake the vial, as this can denature the protein. The vial should be kept in its original carton to protect it from light until the time of use. Once diluted for infusion, the solution is stable for up to 24 hours at refrigerated temperatures or 15 hours at room temperature. Store the medication in a secure, professional medical refrigerator strictly out of the reach of children.

Important Note on Daratumumab 100mg/5ml Injection

The administration of Daratumumab 100mg/5ml Injection is associated with specific procedural risks. Infusion-Related Reactions (IRRs) are very common (occurring in nearly half of patients), especially during the first infusion. Symptoms can include nasal congestion, cough, throat irritation, chills, vomiting, and nausea. Consequently, pre-medication with corticosteroids, antipyretics, and antihistamines is mandatory 1 hour before every infusion to mitigate these reactions.

Blood Bank Interference: Daratumumab binds to CD38 on red blood cells, which can result in a false-positive Indirect Coombs Test. This can complicate blood typing and cross-matching for transfusions. Patients must inform blood bank personnel that they are taking this drug so specific mitigation techniques can be used.

Infection Risk: The drug can deplete immune cells, increasing susceptibility to infections, including reactivation of Herpes Zoster (Shingles). Antiviral prophylaxis (e.g., acyclovir) is recommended within 1 week of starting treatment and continuing for 3 months after treatment stops. By strictly following these professional guidelines and pre-medication protocols, healthcare providers can safely maximize the revolutionary benefits of Daratumumab 100mg/5ml Injection.